...et group consists of MDs, medical institutions and pharmaceutical companies. The unique selling points of the product are objectivity, comparability and precision. In the EU, RA treatments cost 25.1 billion EUR in 2009. With more precise diagnosis and objective follow-up this can be decreased considerably with the AutArt medical device. This project is in line with the 282/2014/EU regulation on t ...